




Named Entity Recognition for the Extraction of Emerging Technological Knowledge from Medical Literature

Sabrina Lamberth-Cocca¹^a, Bernhard Maier¹, Christian Nawroth¹,
Paul Mc Kevitt²^b and Matthias Hemmje¹^c

¹Faculty of Mathematics and Computer Science, University of Hagen, Germany

²Academy for International Science & Research (AISR), Derry/Londonderry, Northern Ireland

Keywords: Named Entity Recognition, Natural Language Processing, Information Retrieval, Knowledge Extraction, Machine Learning, Emerging Medical Technology, Clinical Argumentation Support.

Abstract: In this paper, we show the results of an experimental Information Retrieval System (IRS) prototype to support the detection of emerging medical technology using the method of Named-Entity Recognition (NER). The overall goal is to automatically identify and classify entities and structures in scientific medical articles, which represent the concept of Medical Technologies (MedTech) with high topicality. As a first approach, we combine learning-based NER with rule-based emerging Named-Entity Recognition (eNER). We train a machine-learning model on manually annotated NER candidates representing medical devices. We then match the results with entries from vocabularies containing medical devices according to our definition, using a handcrafted rule-based approach and fuzzy functions. The main outcome is an experimental prototype which we call, MedTech-eNER-IRS, which shows that such an approach works in general, including pointers for further research and prototype improvements.


1 INTRODUCTION


The work presented in this paper is part of the *RecomRatio (Recommendation Rationalization) project* (cf. University of Bielefeld, 2017). The main objective here is to support decision making in various medical areas by developing Information Retrieval (IR) systems for clinical Virtual Research Environments (VREs). *RecomRatio* is a VRE to support argumentation processes of medical staff in determining clinical decisions.


Medical experts need to conduct research based on knowledge sources such as scientific publications for various reasons. One purpose is to gather information about the state of the art, and in particular new technologies in relevant biomedical fields. Databases such as PubMed (NCBI, 2022) support document research in relevant domains, for instance specific diagnostic areas like gene expression analysis. The general problem of information

explosion does not end at the medical domain and leads to a growing volume of literature.

In the case of this study and our experimental prototype, called *MedTech-eNER-IRS*, we observe a problem that is unsolved to the best of our knowledge: detecting Named Entities (NEs) that represent the concept of emerging Medical Technology (MedTech). Whilst the automatic recognition of emerging NEs (eNEs) has already been addressed by Nawroth et al. (2018), current IR systems are not capable of recognizing and classifying MedTech entities. Additionally, existing vocabularies such as MeSH (Medical Subject Headings) (NLM, 2021) and SNOMED CT (Systematized Nomenclature of Medicine – Clinical Terms) (SNOMED International, 2021) can be generally used for medical NER, but do not contain explicit classes for distinguishing MedTech entities, which adds another degree of complexity to the recognition task.

^a <https://orcid.org/0000-0002-8092-5219>

^b <https://orcid.org/0000-0001-9715-1590>

^c <https://orcid.org/0000-0001-8293-2802>

In the following Section 2, we give an overview of the state of the art and related work, followed by a description of how we prepared the experimental data and conducted the preparatory study in Section 3. In Section 4, we present the design and implementation of our experimental prototype, MedTech-eNER-IRS, including use cases, architecture and experimental functions. Section 5 summarizes the evaluation results of the MedTech-eNER-IRS's components. We close this article with a discussion (Section 6), and conclusion and future research (Section 7).

2 STATE OF THE ART AND RELATED WORK

Detecting medical terms from collections of textual documents that are relevant to a specific information need is a problem of Information Retrieval (IR) and Natural Language Processing (NLP). More precisely, the problem can be subsumed under the NLP task of Named Entity Recognition (NER). NER denotes the method of automatically detecting and classifying Named Entities, i.e. named objects from the real world such as persons, organizations, locations, in unstructured text data. In the medical domain, NER focuses on the detection of specific medical terms. For instance, biomedical information extraction applies biomedical NER (BioNER) to detect relevant entities representing genes and diseases, in order to infer relations from text-based publications, e.g., Perera et al. (2020).

2.1 Definition of Medical Technology

In order to define entities for recognition in a NER model, we first need to define the underlying concept. Thus, we first answer the question, what exactly MedTech-eNER-IRS is meant to recognize and classify. In general, medical technology (MedTech) means the, “application of science to develop solutions to health problems or issues such as the prevention or delay of onset of diseases or the promotion and monitoring of good health” (National Center for Health Statistics, 2010, p. 4). The World Health Organization (WHO) defines health technology as the “application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives” (WHO, 2022, para. 2). A similar definition of health technology can be found in the Health Technology Assessment (HTA) glossary: “An intervention developed to prevent, diagnose or treat

medical conditions; promote health; provide rehabilitation; or organize healthcare delivery. The intervention can be a test, device, medicine, vaccine, procedure, program or system” (International Network of Agencies for Health Technology Assessment, 2022).

The European medical devices directive, *Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices*, applies the following definition for medical devices: “any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the following specific medical purposes:

- diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease,
- diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability,
- investigation, replacement or modification of the anatomy or of a physiological or pathological process or state,
- providing information by means of in-vitro examination of specimens derived from the human body, including organ, blood and tissue donations,

and which does not achieve its principal intended action by pharmacological, immunological or metabolic means, in or on the human body, but which may be assisted in its function by such means. The following products shall also be deemed to be medical devices:

- devices for the control or support of conception;
- products specifically intended for the cleaning, disinfection or sterilisation of devices [...]”

(EU, 2020, p. 15).

In-vitro diagnostic devices (IVD) are not part of this directive, but the IVD directive also defines them as medical devices: “in vitro diagnostic medical device means any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information:

- concerning a physiological or pathological state, or
- concerning a congenital abnormality, or
- to determine the safety and compatibility with potential recipients, or
- to monitor therapeutic measures”

(EU, 2012, p. 5).

The United States of America (U.S.) Food and Drug Administration (FDA) uses a similar definition for medical devices:

- “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is
 - (1) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them,
 - (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
 - (3) intended to affect the structure or any function of the body of man or other animals, and
- which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes” (FDA, 2017, p. 5).

Based on the regulatory definitions of the European Union (EU) and the U.S., we use the following shortened and summarized definition of medical technology for all following analyses and MedTech-eNER-IRS.

- *Instrument, apparatus, device, software, machine, appliance, implant, in-vitro reagent for the*
- *Diagnosis, prevention, monitoring, prognosis or treatment of diseases with its*
- *Main effect not through in-vivo biochemical action (no drugs).*

2.2 Characteristics of Emerging Technological Knowledge

The concept of *technology* has both instrumental and processual components and is strongly tied to the concept of *knowledge*. A systemic approach explaining the emergence of new technology distinguishes between *knowledge* (technological know-how), *activities* (problem solving by applying technology), and *artifacts* (problem solution; machines, devices, products; technical systems) as constituents (Bullinger, 1994, p. 32 ff.). Technological knowledge “derives from, and finds meaning, in activity”, is strongly tied to practical applications; tacit knowledge as a form of technological knowledge is embedded in technological activity, and “isolated from activity and removed from the implementing context, much of technological knowledge loses its meaning and identity” (Herschbach, 1995, p. 38).

The difficulty with emerging knowledge and its systematic detection is that it, “arises suddenly and unexpectedly and it cannot be planned and predicted” (Patel and Ghonheim, 2011, p. 425). Thus, the challenging task is to detect entities representing emerging (technological) knowledge that are yet *unknown*, which we define as non-existent in a relevant vocabulary or knowledge base.

We limited our definition of MedTech in the previous section to its instrumental dimension, and thus are focusing on MedTech *artifacts* for MedTech-eNER-IRS discussed here. However, for further refinement, procedural information and application context will be included.

2.3 Emerging Named Entity Recognition (eNER)

Emerging Named Entity Recognition (eNER) is a relatively new research area that deals with the automatic detection of NEs that are useful to automatically extract emerging knowledge according to the definition in the previous section. Nawroth et al. (2018) introduced the concept of emerging Named Entities (eNE) and eNER in order to recognize and classify characteristic NEs in the context of arguments in clinical decisions. According to their definition, eNEs are terms in use that are not acknowledged yet, i.e., not listed in controlled vocabularies or databases. We apply the following formal definition (1) to determine if an NE is an eNE:

$$\text{If } Y_D < Y_{NE} \Rightarrow \text{eNE} \quad (1)$$

Y_D : publication year of documents from text corpus

Y_{NE} : entry year of each entity in a controlled vocabulary or database.

3 EXPERIMENTAL DATA AND PREPARATORY STUDY

In order to discover the patterns of NEs that represent medical technology as well as their appearance in relevant text documents, we conducted a manual corpus analysis and annotation of such NEs.

We analyzed eleven research papers in the field of medical diagnostics from different journals, which had been selected by a medical expert from the field of laboratory diagnostics (see Table 1). Medical devices in the text corpus are referenced to mostly not by using general descriptive terms, but brand names. Additionally, product- or manufacturer names are often incomplete or imprecise. We observed some

patterns, such as *<product name> followed by <manufacturer name>* helpful for rule-based NER.

Table 1: Text corpus of papers in the field of diagnostics.

Text No.	Paper Title	Reference
1	The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases	Kanakry et al. (2016)
2	Cell-Free DNA in blood reveals significant 1 cell, tissue and organ specific injury and predicts COVID-19 severity	Cheng et al. (2020)
3	Assessment of cell free mitochondrial DNA as a biomarker of disease severity in different viral infections	Ali et al. (2020)
4	Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose	Laurent et al. (2020)
5	Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer	Katsutoshi et al. (2017)
6	Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease	Blauwkamp et al. (2018)
7	Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis	Gan et al. (1993)
8	Circulating cell-free nucleic acids: main characteristics and clinical application	Szilágyi et al. (2020)
9	Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases	Yamamoto et al. (1994)
10	Monitoring of cell-free viral DNA in primary Epstein-Barr virus infection	Kimura et al. (1999)
11	A powerful, non-invasive test to rule out infection	O'Grady (2019)

However, the patterns occur in an inconsistent manner. Table 2 shows a list of different patterns and corresponding examples observed in the analyzed text corpus. The results were discussed and validated with the medical expert based on a questionnaire which contained the manually annotated NE candidates that we assumed to represent medical technologies according to the definition above.

Table 2: Different patterns of medical-device naming.

Pattern	Example from text corpus
Device (product name; manufacturer, city, US federal state)	Automated counts (Sysmex KX-21N; Sysmex, Lincolnshire, IL)
Product name (manufacturer, city, US federal state)	QIAmp DNA blood mini reagents (Qiagen, Gaithersburg, MD)
Product name (manufacturer)	Qiagen/Artus EBV analyte specific reagents (Qiagen)
Product name (manufacturer, reference #[Nr])	DNA cryostorage vials (Eppendorf, reference #0030079400)
Product name (manufacturer reference #[Nr])	DNA cryostorage vials (Thermo Scientific #363401)
Device (manufacturer, country of origin)	kit (Machery-Nagel, Germany)
Product name (manufacturer, country of origin)	Eva green qPCR Master mix (Solis Biodyne, Estonia)
Product name contains manufacturer name	Qiagen Circulating Nucleic Acid Kit

4 DESIGN AND IMPLEMENTATION

Our model extends the eNER-IRS (emerging Named Entity Recognition System) by Nawroth et al. (2018) for the recognition of medical technology terms, which we abbreviate as MedTech-NEs and MedTech-eNEs for emerging terms respectively. We first discuss the use cases of the MedTech-eNER-IRS. Then we discuss preparation of the test and evaluation data, the algorithmic constituents of MedTech-eNER-IRS as well as its overall architecture.

4.1 MedTech-eNER-IRS Use Cases

Based on the principles of User-Centered System Design (UCD) (Norman and Draper, 1986), we define first the user context and requirements of the MedTech-eNER-IRS. Overall context is given by the RecomRatio project which aims to support medical experts in decision making by providing them with relevant content from large volumes of text documents such as scientific articles. In particular, the pipeline of MedTech-eNER-IRS is intended to accept unknown texts and present the identified NEs/eNEs as output. In brief, MedTech-eNER-IRS is to fulfill the following two key requirements: (1) Perform NER/eNER in unknown texts; (2) Presentation of the annotated text, i.e. the MedTech-NEs/eNEs.

Derived from this, the use cases supported by MedTech-eNER-IRS are as follows (see Figure 1):

- Transform data: Transforms manually prepared data, as well as raw data from medical vocabularies in a data schema suitable for machines-based processing.
- Provide expert annotations: Provides MedTech-eNER-IRS with the data from the preparatory study, i.e. the manually annotated, validated MedTech-NEs (expert annotations).
- Train statistical model: Trains the learning-based NER/eNER model with the expert annotations using spaCy models.
- Provide vocabulary: Provides MedTech-eNER-IRS with the data for rule-based NER/eNER, including year dates from medical vocabularies for the identification of eNEs.
- Process document: Processes a document of choice by the user from its original raw format through the whole NER/eNER system’s pipeline, including learning-based NER, rule-based NER, and rule-based eNER (see Figure 2).
- Present NEs/eNEs: Presents the results of the MedTech-NER/eNER task to the user.




Figure 1: MedTech-eNER-IRS use cases.

Learning-Based NER: MedTech-eNER-IRS consists of a combination of learning-based and rule-based NER in order to detect emerging MedTech terms. The training and evaluation data were obtained as follows:

- Training data: We used the manually annotated NE candidates representing MedTech.
- Evaluation data: We chose a 5-fold cross-validation, since the training corpus was limited (11 documents).

Rule-Based NER and eNER: Medical vocabularies such as MeSH and SNOMED CT contain terms that can be used for medical NER. However, they are limited to rather general terms related to medical technology, whilst relevant text corpora often contain medical devices and reagents

⁴ Archive files for historical and research purposes

with specific brand names or manufacturer-specific product names. Thus, we additionally used manufacturer-specific databases for training the detection of MedTech-NEs classified as product names and manufacturers: *Premarket Approval (PMA)* (FDA, 2021a), *510(k)* (FDA, 2021b) as well as *Device Registration and Listing* (FDA, 2021c) of the U.S. Food and Drug Administration (FDA).

We identified and extracted the relevant entries of MedTech terms from MeSH and SNOMED CT together with the year date. We used the following versions: *MeSH XML Descriptors 2021*; *SNOMED CT International 20210131*⁴; *Premarket Approval PMA 202109*; *501(k): PMN since 1996* (as per 13 September 2021), *PMN 1991-1995*, *PMN 1986-1990*, *PMN 1981-1985*, *PMN 1976-1980*; *Device Registration & Listing* (as per 06 November 2021).

The year dates are required for the automatic matching of the identified NEs with the vocabulary or database entries, in order to determine, if an NE is an eNE or not. In order to deal with the inconsistent use of naming patterns, we applied fuzzy functions using the *RapidFuzz* library (Bachmann, 2021).




Figure 2: MedTech-eNER-IRS pipeline.

4.2 Architecture and Experimental NER/eNER Functions

The overall architecture of MedTech-eNER-IRS consists of three components according to the Model-View-Control (MVC) design pattern (see Figure 3).

We used the Python programming language in *Jupyter Notebook* (Kluyver et al., 2016) as framework for the realization of the experimental MedTech-eNER-IRS, as well as pretrained models from the NLP library *spaCy* (Honnibal and Montani, 2017): *en_core-sci_lg*, *en_core-web_lg*. From the corpus of 11 documents (323,118 words), 202 annotations (NEs/eNEs) were extracted and used for training. We used the open-source tool *Doccano*⁵ for annotation.

The following code lines illustrate the function to match the year dates for eNE classification.

```
# eNER function to match year dates
def ener(entities, year):
    for entity in entities:
        if int(year) < int(entity._.year):
            entity._.emerging=True
    return entities
```

⁵ <https://github.com/doccano/doccano>




Figure 3: Overall architecture of MedTech-eNER-IRS according to the MVC paradigm.

5 EVALUATION

We evaluated the results of MedTech-eNER-IRS in respect of its three key components: (1) preparatory study, (2) learning-based NER, and (3) rule-based NER/eNER. In this section, we also describe possible improvements to further develop MedTech-eNER-IRS.

Preparatory study: We conducted a qualitative study, in order to generate a training data set as well as a gold standard for testing the results of MedTech-eNER-IRS. This preparatory step was based on a questionnaire with the manually annotated MedTech-NE/eNE candidates that were presented to a medical expert (professor in the field of laboratory diagnostics), who had to choose between “Named Entity”, “emerging Named Entity”, and “No Medical Technology”. The expert had difficulties in classifying many of the cases presented because the context was missing. The unclear cases and the reasons for the difficulties were clarified in a second in-depth interview with the same expert. One key result was that even if a term represents a medical technology, it might be irrelevant in the context of an expert’s specific information need, and thus would not be a relevant NE/eNE to be presented to the user of MedTech-eNER-IRS. Additionally, some terms were borrowed from a domain not known to the expert, e.g., molecular biology, and it was not clear if they were relevant for a specific MedTech application. To improve these deficiencies, methods to automatically determine the descriptivity of identified NE/eNE candidates such as TF-IDF and Word2Vec can be applied.

Learning-based NER: For evaluation of the learning-based model we used the *Scorer* method of spaCy to calculate the metrics *Precision*, *Recall* and *F₁*. Test data were created from the corpus by performing standard text cleaning such as removal of empty lines, irrelevant head- or footnotes or line numbers. Since the training corpus was limited, the spaCy output during training showed an error and the quality of the statistical model was low (F₁: 0.39, Precision: 0.42, Recall: 0.35), which was accepted for the experimental setup, but would be solved in future setups by increasing the corpus size.

Rule-based NER/eNER: Both on the basis of our vocabulary file of MedTech terms, including the naming patterns we found in the manufacturer-specific databases, MedTech-eNER-IRS returned relevant hits. False-positive results occurred several times, mostly due to homonyms or the naming pattern *<product name> contains <manufacturer name>*. Evaluation was not metrics-based due to the low number of validated MedTech-NEs/eNEs.

6 DISCUSSION

We have discussed the modeling and implementation of MedTech-eNER-IRS for the automatic recognition of MedTech-NEs/eNEs. This constitutes the first foundation for an IR system that is capable of identifying entities that represent medical technologies in unknown text documents. Since we identified emerging technology to be a specific key information need of medical experts, we designed MedTech-eNER-IRS to distinguish between MedTech-NEs and MedTech-eNEs, in order to

support the retrieval of the most recent MedTech entities, before they are included in controlled vocabularies. Within the restricted definition of medical technology, we set in advance, the chosen solution path – i.e., the combination of a learning-based and a rule-based NER approach – and the limited corpus size, we conclude the following: The task is basically solvable using the approach of our MedTech-eNER-IRS, but this needs to be improved in terms of: (1) The size of the text corpus and the number of MedTech-NE candidates for training (learning-based NER): these restrictions led to an impasse in terms of the use of metrics for MedTech-eNER-IRS performance evaluation; (2) The sophistication of the entity ruler (rule-based NER): these restrictions led to the limitation of MedTech-eNER-IRS in its recognition of simple MedTech terms such as *tubes*, *gloves*, *pipette tips*, as well as in its inability to recognize terms that are non-exact wording and to avoid false-positives through homonyms like e.g., *chain* (*chain reaction*); (3) The consideration of naming patterns (rule-based NER): the chosen approach led to meaningful hits, e.g. *Sysmex KX-21N*, *QIAmp DNA blood mini reagents*, *Karius diagnostic test*; restrictions led to false-positives, mostly in cases where the name of a MedTech product contains the manufacturer’s name.

7 CONCLUSION AND FUTURE WORK

MedTech-eNER-IRS is being further developed against the background of limitations discussed in Section 6, as well as in terms of further observations that go beyond the definition of medical technology assumed here. We name three strategies for improving the performance of MedTech-eNER-IRS: (1) refining the machine-learning model, (2) supporting annotation of training data by automatically determining the descriptivity of NE candidates, and (3) using procedural representations of technological descriptions.

To improve our limited NER/eNER machine-learning model, we propose to use fine-tuned, pre-trained language models such as BioBERT (Lee et al., 2019), and for this purpose also increase the volume of training data. To alleviate work in manual labelling in extensive training corpora and increase the efficiency of an expert-based generation of gold standards, the approach needs to be automated. To prevent MedTech-NE candidates to be non-descriptive and irrelevant to medical experts in specific contexts, techniques such as TF-IDF (Term Frequency - Inverse Document Frequency) (cf.

Sammut and Webb, 2011) and Word2Vec (Mikolov et al., 2013) can be used.

For the sake of a first proof of concept and simplicity of MedTech-eNER-IRS, we narrowed the definition of medical technology down to technical artifacts. The concept of medical technology – as is the case with the concept of technology in general – is actually more complex than representing tangibles only. The more general definitions of health technology show that intangible aspects are also relevant, referring to the concepts of *knowledge* and *science*. During corpus analysis and research of scientific definitions of technology we found evidence that: (1) Technological terms are embedded in procedural descriptions within medical articles, in particular in the common section “materials and methods”, and (2) the systemic perspective on the concept of technology supports this observation by defining it based on the constituents, *knowledge*, *activities*, *artifacts* (Bullinger 1994). Processing and mining procedural knowledge from natural-language data is an additional NLP task that can be used to extract emerging medical technology. Procedural knowledge can be described using a semantic representation, “by specifying semantic elements of a procedure and their interrelated information” (Zhang et al., 2012, p. 522). This has been demonstrated by task-based extraction of procedural knowledge from text in case of cooking recipes (Schumacher et al., 2012), with *tasks* being smaller units of *activities*, and *activities* being indicated by *verbs*.

REFERENCES

- Ali, Z., Waseem, S., Anis, R.A., Anees, M. (2020). Assessment of cell free mitochondrial DNA as a biomarker of disease severity in different viral infections. In *Pak J Med Sci*, Vol. 36 No. 5, 860-866.
- Bachmann, M. (2021). RapidFuzz 2.3.0 documentation. <https://maxbachmann.github.io/RapidFuzz/index.html>.
- Blauwkamp, T.A., Thair, S., Rosen, ... Yang, S. (2018). Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. In *Nat Microbiol*, 4, 663-674.
- Bullinger, H.-J. (1994). *Einführung in das Technologiemanagement*. B.G. Teubner. Stuttgart.
- Cheng et al., 2020: Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity. In *medRxiv preprint*.
- EU (2012). *Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices*.
- EU (2020). *Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No*

- 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC.
- Explosion (2022). *displaCy Named Entity Visualizer*.
- FDA (2017). *Classification of Products as Drugs and Devices and Additional Product Classification Issues: Guidance for Industry and FDA Staff*. U.S. Food and Drug Administration.
- FDA (2021a). *Premarket Approval (PMA)*. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>.
- FDA (2021b). *Downloadable 510(k) Files*. <https://www.fda.gov/medical-devices/510k-clearances/downloadable-510k-files>.
- FDA (2021c). *Device Registration and Listing*. <https://www.fda.gov/medical-devices/how-study-and-market-your-device/device-registration-and-listing>.
- Gan, Y.-J., Sullivan, J.L., Sixbey, J.W. (1993). Detection of Cell-Free Epstein-Barr Virus DNA in Serum during Acute Infectious Mononucleosis. In *JID* 170, 436-439.
- Herschbach, D.R. (1995). Technology as Knowledge. In *Journal of Technology Education*, Vol. 7 No. 1.
- Honnibal, M., Montani, I. (2017). *spaCy 2: Natural language understanding with Bloom embeddings, convolutional neural networks & incremental parsing*.
- International Network of Agencies for Health Technology Assessment (INAHTA) (2022). *Health technology*. <http://htaglossary.net/health-technology>.
- Kanakry, A., Hegde, A.M., Durand, C.M., Massie, A.B., Greer, A.E., Ambinder, R.F., Valsamakis, A. (2016): The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. In *BLOOD*, 21 APRIL 2016 x VOLUME 127, NUMBER 16.
- Katsutoshi Shoda, K., Ichikawa, D, Fujita, Y., Masuda, K.; Hiramoto, H., Hamada, J., Arita, T., Konishi, H., Kosuga, T., Komatsu, S., Shiozaki, A., Okamoto, K., Imoto, I., Otsuji, E. (2017). Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. In *Oncotarget*, 2017, Vol. 8, (No. 17), 28796-28804.
- Kimura, H., Nishikawa, K., Hoshino, Y., Sofue, A., Nishiyama, Y., Morishina, T. (1999). Monitoring of cell-free viral DNA in primary Epstein-Barr virus infection. In *Med Microbiol Immunol* 188, 197-202.
- Kluyver, T., Ragan-Kelley, B., Fernando Perez, Granger, B., Bussonnier, M., Frederic, J., ... Willing, C. (2016). Jupyter Notebooks. In *F. Loizides, B. Schmidt (Eds.), Positioning and Power in Academic Publishing: Players, Agents and Agendas* (87-90).
- Laurent, D., Semple, F., Philip J., Lewis, S., Rose, E., Black, H.A., Coe, J., Forbes, S.J., Arends, M.J., Dear, J.W., Aitman, T.J. (2020). Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose. In *BMC Medical Genomics* (2020), 13-60.
- Lee, J., Yoon, W., Kim, S., Kim, D., Kim, S., So, C.H., Kang, J. (2019). BioBERT: a pre-trained biomedical language representation model for biomedical text mining. In *Bioinformatics*, 2019, 1-7.
- Mikolov, T., Chen, K., Corrado, G., Dean, F. (2013). *Efficient Estimation of Word Representations in Vector Space*. arXiv:1301.3781.
- National Center for Health Statistics (2010). *Health, United States, 2009*. Hyattsville, MD.
- Nawroth, C., Engel, F., Eljasik-Swoboda, T., Hemmje, M. (2018). Towards Enabling Emerging Named Entity Recognition as a Clinical Information and Argumentation Support. In *DATA 2018*, 47-55.
- NCBI (2021). *PubMed*. <https://pubmed.ncbi.nlm.nih.gov>.
- NLM (2021). *Medical Subject Headings*. <https://meshb.nlm.nih.gov>.
- Norman, D.A., Draper, S.W. (1986). *User Centered System Design*, CRC Press. London.
- Nunamaker, J., Chen, M., Purdin, T. (1991). Systems development in information systems research. In *J Management Information Systems*, 7, 89-106.
- O'Grady, J. (2019). A powerful, non-invasive test to rule out infection. In *NATURE Microbiology*, VOL 4, APRIL 2019, 554-555.
- Patel, N.V., Ghonheim, A. (2011). Managing emergent knowledge through deferred action design principles: The case of ecommerce virtual teams. In *Journal of Ent Info Management*, 24(5), 424-439.
- Perera, N., Dehmer, M., Emmert-Streib, F. (2020). Named Entity Recognition and Relation Detection for Biomedical Information Extraction. In *Front. Cell Dev. Biol.*, 28 August 2020.
- Sammut, C., Webb, G.I. (eds.) (2011). *Encyclopedia of Machine Learning*. Springer, Boston, MA.
- Schumacher, P., Minor, M., Walter, K., Bergmann, R. (2012). Extraction of Procedural Knowledge from the Web. A comparison of two workflow extraction approaches. In *WWW 2012 Companion, April 16-20, 2012, Lyon, France*. ACM 978-1-4503-1230-1/12/04.
- SNOMED International (2021). *SNOMED CT Release File Specifications*. <https://www.snomed.org/rfs>.
- Szilágyi M, Pös O, Márton É, Buglyó G, Soltész B, Keserű J, Penyige A, Szemes T, Nagy B (2020). Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. In *Int J Mol Sci*. 2020 Sep 17;21(18):6827.
- University of Bielefeld (2017). *Rationalizing Recommendations (RecomRatio)*. <http://ratio.sc.cit-ec.uni-bielefeld.de/projects/recomratio/>.
- WHO (2022). *What is a health technology?* <https://www.euro.who.int/en/health-topics/Health-systems/health-technologies-and-medicines/policy-areas/health-technology-assessment>.
- Yamamoto, M., Kimura, H., Hironaka, T., Hirai, K., Hasegawa, S., Kuzushima, K., Shibata, M., Morishima, T. (1994). Detection and Quantification of Virus DNA in Plasma of Patients with Epstein-Barr Virus-Associated Diseases. In *J Clin Microbiol*, Vol. 33, No. 7, July 1994, 1765-1768.
- Zhang, Z., Webster, P., Uren, V., Varga, A., Ciravegna, F. (2012). Automatically Extracting Procedural Knowledge from Instructional Texts using Natural Language Processing. In *LREC'12*.